A Phase 1, 2-part, Open-label, Fixed-sequence Study Evaluating Potential Drug-drug Interactions Between Gemfibrozil (Part 1) or Dabigatran Etexilate (Part 2) and Camlipixant (BLU-5937) 50 mg Tablet in Healthy Participants Under Fasting Conditions
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Camlipixant (Primary) ; Dabigatran etexilate (Primary) ; Gemfibrozil (Primary)
- Indications Cough
- Focus Pharmacokinetics
- Sponsors BELLUS Health
Most Recent Events
- 14 Feb 2024 Status changed from not yet recruiting to completed.
- 27 Jul 2023 New trial record